New cocktail of drugs takes on tough pancreatic cancer

NCT ID NCT05481476

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of three drugs—surufatinib, sintilimab, and a standard chemotherapy (nab-paclitaxel plus gemcitabine)—as a first treatment for people with advanced or metastatic pancreatic cancer. The study enrolled 32 participants and aims to see how many respond to the treatment. It is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: surufatinib, sintilimab, nab-paclitaxel, gemcitabine
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced pancreatic cancer, potentially slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 32 participants and no comparison group. The combination may cause significant side effects and may not prove more effective than standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC NEOPLASMS

Contacts and locations

Locations

Cancer center of SunYat-sen University

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.